ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1324

Treatment Patterns in Women with Post-Menopausal Osteoporosis Using Abaloparatide: A Real-world Observational Study

Deborah Gold1, Tammy Beckett2, Chad Deal3, Andrew L James4, Jacqueline M Kernaghan5, Mahshid Mohseni6, Abigail McMillan7, Tom Bailey7, Leny Pearman8, John Caminis8, Yamei Wang8 and Setareh A Williams9, 1Duke University Medical Center, Durham, NC, 2Department of Orthopaedics, Orthopaedic Associates of Grand Rapids Research and Education Institute, Grand Rapids, MI, 3Cleveland Clinic, Shaker Heights, OH, 4Columbia Orthopaedic Groups LLP, Columbia, MO, 5Prospect Health Access Network, Springfield, PA, 6Washington University School of Medicine, St. Louis, MO, 7Observational Research Adelphi Real World, Macclesfield, United Kingdom, 8Radius Health, Inc., Waltham, MA, 9CobbsCreek Healthcare, Newtown Square, PA

Meeting: ACR Convergence 2022

Keywords: Clinical Osteoporosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Abaloparatide (ABL) is approved for treatment of women with postmenopausal osteoporosis (PMO) at high risk for fracture. The study evaluated real-world treatment patterns for patients new to ABL regardless of treatment history for osteoporosis (OP).

Methods: This multi-center retrospective study collected data from six academic and clinical practice settings across the US. Patients had to be on ABL for ≥ 1 month prior to enrollment. Follow-up data were collected retrospectively from medical records between December 2020 and August 2021.

Results: A total of 173 patients met the eligibility criteria. Mean age (SD) was 69.8 (7.4) at the time of data collection. Prior to the initiation of ABL, 23.1% reported a fracture, 78.6% of patients had received treatment for OP, of whom 26% had taken teriparatide. The mean (SD) time from discontinuation of an OP medication and initiation of ABL was 20.5 (38.4) months. Over the 24-month follow-up period, 96% of the patients had at least one follow-up visit for management of OP with a median of 3 outpatient consultations. Approximately 24 months of follow-up data since ABL initiation was collected from 94% of patients. Six percent of patients had between 12-24 months of follow-up data. Most patients (55.5%) had access to a medication support program. Patients who completed treatment with ABL received it for a median of 18.6 months with median cumulative exposure to anabolic for 22.5 months. Few patients (5.6%) had gaps in treatment with ABL with a mean (SD) gap of 62.4 (90.5) days. The most common reasons for discontinuation of treatment were financial (11.1%) and adverse events associated with tolerability (8.0%). The observed mean (SD) duration of treatment was longer for patients previously treated for OP compared with those not previously treated 18.0 (8.2) vs. 14.6 (7.3) months. Following treatment with ABL, 51% (n=82) of patients were predominantly prescribed either denosumab (49%, n=40), zoledronic acid (24%, n=20) and teriparatide (11%, n=9). The median time between completion of a course of treatment of ABL and beginning of an OP drug was 21 days, with the maximum time between therapies reported as 12.3 months.

Conclusion: The majority of patients in these clinical settings completed the full course of therapy as prescribed. Consistent with clinical practice guidelines, most patients continued with an antiresorptive. This favorable observed pattern may be a result of the care pathway at these specialized bone health centers, including frequency follow-up visit and accessibility to both medication and patient support services.


Disclosures: D. Gold, Radius Health; T. Beckett, Radius Health; C. Deal, Radius Health, Amgen, Inc., Eli Lilly; A. James, Amgen, Inc; J. Kernaghan, Radius Health, Amgen Inc; M. Mohseni, None; A. McMillan, None; T. Bailey, None; L. Pearman, Radius Health; J. Caminis, Radius Health; Y. Wang, Radius Health; S. Williams, None.

To cite this abstract in AMA style:

Gold D, Beckett T, Deal C, James A, Kernaghan J, Mohseni M, McMillan A, Bailey T, Pearman L, Caminis J, Wang Y, Williams S. Treatment Patterns in Women with Post-Menopausal Osteoporosis Using Abaloparatide: A Real-world Observational Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/treatment-patterns-in-women-with-post-menopausal-osteoporosis-using-abaloparatide-a-real-world-observational-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-patterns-in-women-with-post-menopausal-osteoporosis-using-abaloparatide-a-real-world-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology